Literature DB >> 34477219

Novel KMT2B mutation causes cerebellar ataxia: Expanding the clinical phenotype.

Joana Damásio1,2,3, Mariana Santos2, Raquel Samões1, Maria Araújo4, Mafalda Macedo4, Ana Sardoeira1, Sara Cavaco5, Joel Freitas6, José Barros1,7, Jorge Oliveira2,3, Jorge Sequeiros2,3,7.   

Abstract

Hereditary cerebellar ataxias comprise a heterogeneous group of neurodegenerative disorders affecting the cerebellum and/or cerebellar pathways. Next-generation sequencing techniques have contributed substantially to the expansion of ataxia-causing genes, including genes classically described in alternative phenotypes. Herein, we describe a patient with adult-onset cerebellar ataxia, minor dystonia, neuropathy, seizure and ophthalmological pathology, who bears a novel variant in KMT2B (NM_014727.2:c.3334 + 1G > A). Bioinformatic analysis suggested this variant completely abolished the splice-site at exon 8/intron 8, which was confirmed through analysis of mRNA extracted from fibroblasts. Exon 8 skipping would ultimately translate as an in-frame deletion at the protein level, corresponding to the loss of 91 aminoacids [p.(Gly1020_Asn1111del)]. So far, KMT2B disease causing variants have been described in patients with dystonia or neurodevelopmental delay, with no reports of a cerebellar predominant phenotype. Our findings highlight the possible role of KMT2B as a gene involved in hereditary cerebellar ataxias.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  KMT2B; cerebellar ataxia; dystonia; genetics

Mesh:

Substances:

Year:  2021        PMID: 34477219     DOI: 10.1111/cge.14055

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  1 in total

1.  A novel synonymous KMT2B variant in a patient with dystonia causes aberrant splicing.

Authors:  Bianca R Grosz; Stephen Tisch; Michel C Tchan; Victor S C Fung; Paul Darveniza; Avi Fellner; Manju A Kurian; Alison McLean; Susan E Tomlinson; Renee Smyth; Sophie Devery; Kathy H C Wu; Marina L Kennerson; Kishore R Kumar
Journal:  Mol Genet Genomic Med       Date:  2022-03-16       Impact factor: 2.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.